Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) recently launched its 4008A dialysis machine to treat patients in China, who are suffering from the end-stage renal disease (ESRD). This latest move further fortifies the company’s foothold in the Asia Pacific dialysis care market.
Following the announcement, shares of this Zacks Rank #3 (Hold) company inched up 0.5% to $35.02 at close.
For investors’ notice, ESRD is the stage in kidney disease when a person's kidneys permanently stop working. The patient requires a long-term dialysis or a kidney transplant.
More on the News
Fresenius Medical’s 4008A dialysis machine is a major breakthrough and an outcome of the collaboration between the Fresenius Medical Care China Design Center in Shanghai and the company’s research and development teams in Germany.
The machine is specially designed to treat a vast number of patients and also ideal for use in remote locations.
Fresenius Medical also announced an initiative dedicated toward providing care and education to nephrologists, nursing staff and patients in areas with inadequate health care resources in China.
Strong Presence in APAC
In China, there are more than 600,000 patients with access to dialysis but the estimated ESRD prevalence is much higher. As part of the ‘Healthy China 2030’ initiative, the government of China has been making efforts to expand the reach of quality medical resources to rural areas in recent times.
It is encouraging to note that, earlier this year, Fresenius Medical launched the 4008A dialysis machine in India as well.
In the recent past, the leading dialysis provider widened its footprint in in the APAC region by acquiring large shares in multiple Chinese companies and hospital systems.
In fact, in the last reported quarter, Fresenius Medical saw strong organic growth in the APAC region.
Market Prospects
Research and Markets projects the APAC dialysis market to witness a CAGR of 7.3% by 2023. Increasing cases of ESRDs and rise in diabetic cases are currently favoring the market.
Price Performance
We believe that these above-mentioned tailwinds will boost the stock that has plunged 31.4% compared with the industry’s 5.9% decline in a year’s time.
Key Picks
A few better-ranked stocks in the broader medical sector are Baxter International (BAX - Free Report) , CONMED Corporation (CNMD - Free Report) and Masimo Corporation (MASI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter’s long-term earnings are expected to grow 12.8%.
CONMED’s long-term earnings are projected to increase 12.8%.
Masimo’s long-term earnings are estimated to rise 20.5%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) recently launched its 4008A dialysis machine to treat patients in China, who are suffering from the end-stage renal disease (ESRD). This latest move further fortifies the company’s foothold in the Asia Pacific dialysis care market.
Following the announcement, shares of this Zacks Rank #3 (Hold) company inched up 0.5% to $35.02 at close.
For investors’ notice, ESRD is the stage in kidney disease when a person's kidneys permanently stop working. The patient requires a long-term dialysis or a kidney transplant.
More on the News
Fresenius Medical’s 4008A dialysis machine is a major breakthrough and an outcome of the collaboration between the Fresenius Medical Care China Design Center in Shanghai and the company’s research and development teams in Germany.
The machine is specially designed to treat a vast number of patients and also ideal for use in remote locations.
Fresenius Medical also announced an initiative dedicated toward providing care and education to nephrologists, nursing staff and patients in areas with inadequate health care resources in China.
Strong Presence in APAC
In China, there are more than 600,000 patients with access to dialysis but the estimated ESRD prevalence is much higher. As part of the ‘Healthy China 2030’ initiative, the government of China has been making efforts to expand the reach of quality medical resources to rural areas in recent times.
It is encouraging to note that, earlier this year, Fresenius Medical launched the 4008A dialysis machine in India as well.
In the recent past, the leading dialysis provider widened its footprint in in the APAC region by acquiring large shares in multiple Chinese companies and hospital systems.
In fact, in the last reported quarter, Fresenius Medical saw strong organic growth in the APAC region.
Market Prospects
Research and Markets projects the APAC dialysis market to witness a CAGR of 7.3% by 2023. Increasing cases of ESRDs and rise in diabetic cases are currently favoring the market.
Price Performance
We believe that these above-mentioned tailwinds will boost the stock that has plunged 31.4% compared with the industry’s 5.9% decline in a year’s time.
Key Picks
A few better-ranked stocks in the broader medical sector are Baxter International (BAX - Free Report) , CONMED Corporation (CNMD - Free Report) and Masimo Corporation (MASI - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter’s long-term earnings are expected to grow 12.8%.
CONMED’s long-term earnings are projected to increase 12.8%.
Masimo’s long-term earnings are estimated to rise 20.5%.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BAX - FREE
Get the latest research report on CNMD - FREE
Get the latest research report on MASI - FREE
Get the latest research report on FMS - FREE